Bukwang Signs with Dainippon for Blonanserin

Published: 2004-12-09 06:54:00

Updated: 2004-12-09 06:54:00

Bukwang Pharmaceuticals announced the signing of a Letter of Intent (LOI) with Dainippon Pharmaceutical Co. Ltd. that provides Bukwang with exclusive licensing rights for blonanserin, an original antipsychotic agent from Dainippon, which is currently undergoing Phase 3 clinical trial in Japan.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK